Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Oktober 2024

Genmab — Oktober 2024

Planlagt Fastgjort Låst Flyttet Genmab
991 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • G Offline
    G Offline
    gentogen
    wrote on sidst redigeret af
    #970

    Den estimerede 12-måneders OS-rate var 65,5 % (95 % konfidensinterval: 49,9-77,4) i TV-gruppen og 32,3 % (95 % konfidensinterval: 19,3-46,1) i kemoterapigruppen.

    1 Reply Last reply
    0
    • T Offline
      T Offline
      Teller
      wrote on sidst redigeret af
      #971

      Man kan vel sige der er indgået aftaler, hvor det er JJ der bestemmer værdien af CD38, ihvertfald inden for MM. Spørgsmålet er så, hvor meget af Genmab's værdi der lige nu er hæftet til en "Opt-In"? Meget værdi er trods alt hældt ud igen...

      1 Reply Last reply
      0
      • StockBullS Offline
        StockBullS Offline
        StockBull
        wrote on sidst redigeret af
        #972

        Pipeline succes, såsom for GEN1046 eller GEN1042, hvor markedet har lav
        forventninger er kurstriggrs når / hvis der kommer nop-notch data. P.t har markedet lav forventning til hele genmabs pipeline

        1 Reply Last reply
        0
        • StockBullS Offline
          StockBullS Offline
          StockBull
          wrote on sidst redigeret af
          #973

          Værdiskabende indlicensering er vel en del af Genmabs strategi, og det rejser spørgsmålet: Må der snart være noget i pipelinen, som de kan sælge?

          1 Reply Last reply
          0
          • StockBullS Offline
            StockBullS Offline
            StockBull
            wrote on sidst redigeret af
            #974

            Med virksomhedens betydelige ressourcer og innovative forskning er det rimeligt at forvente, at der snart vil blive introduceret nye produkter eller teknologier, som kan generere yderligere indtægter gennem licensering. Spændende hvad Jan disker op med i næste uge.

            1 Reply Last reply
            0
            • StockBullS Offline
              StockBullS Offline
              StockBull
              wrote on sidst redigeret af
              #975

              JPM har peaksalg på 5miausd. Den betydelige op- og nedadgående risiko for aktiekursen omkring JNJs opt-in-beslutning
              på HexabodyCD38 (HBCD38), sandsynligvis tidligt i 2025, hvor der både er begrænsede kliniske data
              som man kan se på fra et klinisk perspektiv, og hvor JNJ også har ydet meget
              lidt kommentar til dets niveau af interesse for programmet. Vi modellerer i øjeblikket 50% POS af
              en opt-in og $5 mia. topsalg.

              1 Reply Last reply
              0
              • StockBullS Offline
                StockBullS Offline
                StockBull
                wrote on sidst redigeret af
                #976

                POS, eller "Probability of Success" (sandsynligheden for succes)

                1 Reply Last reply
                0
                • L Offline
                  L Offline
                  lahn1
                  wrote on sidst redigeret af
                  #977

                  EL 13:10, yes wired, makes it sund like TV is working better in J pys. But the info that is WAS 11.5 vs 8.5 I guess tells that this just might be a new data cut? and it would cover alle pts and not only J pts. J is used to have J-specific aren't they ? so could be when it's an international trial they make sure to highlight, that it also works in J pts ? my guess

                  1 Reply Last reply
                  0
                  • StockBullS Offline
                    StockBullS Offline
                    StockBull
                    wrote on sidst redigeret af
                    #978

                    Genmab A/S(Neutral; Price Target: Dkr 2,050)
                    Investment Thesis
                    We rate Genmab Neutral, noting:
                    (1.) The significant shareprice upside and downside risk around JNJ’s opt-in decision
                    on HexabodyCD38 (HBCD38), likely early 2025, where there is both limited clinical data
                    on which to take a view from a clinical perspective, and where JNJ has also provided very
                    little commentary on it’s level of interest in the program. We currently model 50% POS of
                    an opt-in and $5bn peak sales.

                    1 Reply Last reply
                    0
                    • L Offline
                      L Offline
                      lahn1
                      wrote on sidst redigeret af
                      #979

                      but would be nice to see an international news flash comfirming this.

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #980

                        Og angående aktieprisen så er jeg gået hen og blevet apatisk. Den er lagt i skuffen og så kigger jeg på den når JnJ har taget stilling til optionen. det er under alle omstændigheder en long hold for mig. 🙂

                        1 Reply Last reply
                        0
                        • StockBullS Offline
                          StockBullS Offline
                          StockBull
                          wrote on sidst redigeret af
                          #981

                          det jo den fra august hvor de downgradede til 2050 så old news

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #982

                            @14.38 it is definitely a new data set/cut, and specifically on Japanese patients. The question is if an update of the earlier ESMO data ex-Japan would give a similar improvement? Or does it only work for Japanese patients? Or has for example better toxicity management improved results/ allowed patients to stay on the drug longer? Either way, I would like to know

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #983

                              Anyway it seems good news as Japan is a big market for cervical cancer. Probably why shares are up so much today.... 😞

                              1 Reply Last reply
                              0
                              • L Offline
                                L Offline
                                lahn1
                                wrote on sidst redigeret af
                                #984

                                Had it translated, that helped 😉 great result but can’t see any new date for data ? I hope its new or the remaining pts groups’ data will suffer from this subgroup of Japanees doing so well i guess

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #985

                                  There are responders in ongoing pilot trial of Daratumumab for ME/CFS. Now researchers are planning a placebo controlled trial https://x.com/TimofejM77894/status/1851978525726679119

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #986

                                    I Think i’ll volunteer in that trial. So tired of the current Stock Price.

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gdn55
                                      wrote on sidst redigeret af
                                      #987

                                      Gad vide om de forsøger at kører den ned i nul. Længere ned kan vi trods alt ikke komme.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #988

                                        Joke of the week award goes to Bulder :-0

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #989

                                          hey i see i discovered a new emoticon by accident 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper